Published: March 17, 2026

Weight Loss Medications May Improve Outcomes for Patients with Chronic Sinus Disease

Research shows GLP-1R agonists may be associated with reduced need for revision sinus surgery and biologic therapies in patients with obesity.

AAO-HNSF

Shutterstock 2655228627A study published in Otolaryngology–Head and Neck Surgery, the peer-reviewed journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation, reveals that glucagon-like peptide-1 receptor agonists (GLP-1RAs)—a class of medications primarily used for weight loss and diabetes management—may significantly improve post-surgical outcomes for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and obesity.

The retrospective cohort analysis examined data from 1,391 matched pairs of adult patients with CRSwNP, obesity, and at least one prior functional endoscopic sinus surgery (FESS). At one-year follow-up, patients taking GLP-1RAs showed a 36% reduction in the need for revision sinus surgery. Additionally, at five years post-surgery, patients experienced a 40% reduction in revision surgery rates and a 28% decrease in first-time biologic prescriptions.

"Using real-world EHR data, our study found that among patients with chronic rhinosinusitis with nasal polyps and obesity, those treated with GLP-1 receptor agonists had lower rates of revision sinus surgery and need for additional therapies, including biologics, over a five-year period. As a retrospective database study, these findings are observational and highlight the need for future prospective research to better understand causality and underlying mechanisms," said Mohamad R. Chaaban, MD, MSCR, MBA, corresponding author for the paper with the Cleveland Clinic Head and Neck Institute. 

The study utilized the TriNetX Analytics platform to analyze data from more than 100 million patient records across 59 healthcare organizations in the United States. Researchers examined patients who received GLP-1RA prescriptions—including semaglutide, dulaglutide, and liraglutide—at least one day after sinus surgery. They compared their outcomes with those of similar patients who did not receive these medications.

The mechanisms behind these improvements may be twofold. Previous research has shown that GLP-1RAs have anti-inflammatory effects in airway tissues, including reducing interleukin-33 (IL-33) production in nasal epithelial cells. IL-33 has been associated with postoperative recurrence in patients with nasal polyps. Additionally, weight loss achieved through these medications may reduce the inflammatory burden associated with obesity, which has been increasingly recognized as a risk factor for chronic rhinosinusitis.

With obesity rates continuing to rise in the U.S. and chronic rhinosinusitis affecting millions of Americans, these findings have important implications for managing both conditions. However, the authors note that prospective studies and mechanistic research are needed to confirm these associations and better understand how GLP-1RAs influence chronic sinus disease outcomes.

Learn More

Learn more by listening to this podcast, featuring Otolaryngology–Head and Neck Surgery Editor-in-Chief Cecelia E. Schmalbach, MD, MSc, who speaks with senior author Dr. Chaaban and Associate Editor Dana L. Crosby, MD, regarding the meaningful connection between chronic rhinosinusitis and obesity. 

Reference

Hoying, D., Kaelber, D.C., and Chaaban, M.R. (2026). Assessing the Impact of GLP-1R Agonists in Post-sinus Surgery Management. Otolaryngol Head Neck Surg, 174: 99-104. https://doi.org/10.1002/ohn.70072

More from April 2026 – Vol. 45, No. 4
Pearls From Your Peers Logo Web
Treating Professional Voice in the Community
Objective findings need to be weighed alongside the singer’s lived experience so that expectations are realistic and responsibility is shared.
Shutterstock 2267438091
AI as a Cognitive Co-Pilot within Laryngology Training and Practice
By grounding training in a framework of critical appraisal and ethical oversight, we ensure that AI tools improve the analysis of data-heavy diagnostics without devaluing the human expertise at the heart of patient care.
Opps Bo M Insights 1500x845
Chronic Care Management in Otolaryngology: A Practical Guide
CCM is a Medicare-recognized service outside of face-to-face visits that provides ongoing care coordination for patients with chronic conditions.
April26 Valdez Park
New Imaging Technique Could Transform Precision of Vocal Fold Injection Procedures
Shortwave infrared imaging offers a new path to better patient outcomes.
Operation of Hope Team
Stories From the Road: Operation of Hope, Bohol, Philippines
Humanitarian efforts empower local health systems, improve continuity of care, and ensure that communities retain long-term benefits of support long after international volunteers depart.
Jackie Cole, Director, Creative Services
Staff Spotlight: Jackie Cole, Director, Creative Services
“I’ve always been a creative problem solver who cares deeply about people. I love using color and design to communicate messages effectively, and in this role, I get to support our members while helping the public and patient population through visual storytelling.”